Shots:

• Celgene & Exscientia enter into a 3yrs. partnership to accelerate the development of small molecules for three therapeutic programs for Celgene using Exscientia’s Centaur Chemist AI drug discovery platform in oncology & autoimmunity
• Exscientia to receive $25M upfront & regulatory & commercial milestone on a future sale of products resulting from the collaboration
• Exscientia’s Centaur Chemist platform improves drug efficacy & speed of delivery of new treatments. Exscientia also collaborated with GSK- Sanofi- Roche- and Evotec for its AI technology

Click here to read full press release/ article | Ref: Exscientia | Image: Endpoints News